FLT3

FLT3

FLT3 (Fms-like tyrosine kinase 3, CD135) is a protein that in humans is encoded by the FLT3 gene.The class III receptor tyrosine kinase family includes FLT3, a cytokine receptor. FLT3 is the cytokine Flt3 ligand (FLT3L)'sreceptor. On the surface of many hematopoietic progenitor cells, FLT-3 is expressed. The normal development of hemopoietic stem cells and progenitor cells depends on FLT3 signaling. One of the genes with the highest frequency of mutations in acute myeloid leukemia (AML) is FLT3.Furthermore, high FLT3 levels in blast cells from some AML patients without FLT3 mutations have been observed. The prognosis may be worse when these levels are high. Cell proliferation, differentiation, and survival are influenced by FLT3 signaling. FLT3 is crucial for the growth of lymphocytes (B and T cells), but not for the growth of other blood cells. The cytokines TNF-Alpha and TGF-Beta both inhibit FLT3 activity.

FLT3 related products

Structure Cat No. Product Name CAS No. Product Description
V77277 AKN-028 acetate
V0587 AMG 925 (FLX925; AMG925) 1401033-86-0 AMG 925 (also called FLX-925; AMG-925) is a novel, potent, selective and orally bioavailable FLT3/CDK4 dual inhibitor with potential antitumor activity.
V11821 ATH686 853299-52-2 ATH686 is a novel and selective FLT3 Inhibitor.
V33217 BPR1J-097 1327167-19-0 BPR1J-097 is a potent FLT3 inhibitor with an IC50 of 11 nM.
V77188 BPR1J-097 Hydrochloride
V0588 Denfivontinib (G-749) 1457983-28-6 G-749 (G749) is a novel and potent FLT3 inhibitor with potential antineoplastic activity.
V69486 Emavusertib hydrochloride (CA-4948 hydrochloride) 2376399-42-5
V78480 FLT3-IN-20
V79168 FLT3-IN-22
V79348 FLT3-IN-23
V31516 FLT3-IN-3 2229050-90-0 FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.
V2632 FLT3-IN-4 2304799-09-3 FLT3-IN-4 is a novel,potent and orally effective Fms-like tyrosine receptor kinase 3 inhibitor(FLT3; IC50=7 nM).
V3135 Gilteritinib hemifumarate 1254053-84-3 Gilteritinib hemifumarate (ASP2215; ASP-2215 hemifumarate; Xospata), the hemifumarate salt of Gilteritinib (ASP2215), is a marketed anti-AML drug acting as a dual inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL respectively.
V3134 Gilteritinib(ASP2215) 1254053-43-4 Gilteritinib (formerly ASP-2215; ASP2215; Trade name: Xospata) is a potent small-molecule inhibitor of FLT3/AXL approved for treating acute myeloid leukemia (AML).
V78738 HSK205
V78308 LT-850-166
V2595 Merestinib (LY2801653) 1206799-15-6 Merestinib (LY-2801653) is a novel, potent, orally bioavailable, type-II ATP competitive, slow-off small molecule inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min.
V5202 MRX-2843 (UNC2371) 1429882-07-4 MRX-2843 (also known as MRX2843; UNC-2371) is a novel, potent and orally bioactivesmall-molecule inhibitor of MERTK and FLT3 with anticancer activity.
V79535 PLM-101
V0584 Quizartinib (AC220; AC010220) 950769-58-1 Quizartinib (formerly also know as AC-220; AC-010220,brand name Vanflyta in Japan) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.
Contact Us